KR101910779B1 - Fgfr1 세포밖 도메인 조합치료 - Google Patents
Fgfr1 세포밖 도메인 조합치료 Download PDFInfo
- Publication number
- KR101910779B1 KR101910779B1 KR1020187012882A KR20187012882A KR101910779B1 KR 101910779 B1 KR101910779 B1 KR 101910779B1 KR 1020187012882 A KR1020187012882 A KR 1020187012882A KR 20187012882 A KR20187012882 A KR 20187012882A KR 101910779 B1 KR101910779 B1 KR 101910779B1
- Authority
- KR
- South Korea
- Prior art keywords
- fgfr1
- ecd
- val
- ser
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41394010P | 2010-11-15 | 2010-11-15 | |
| US61/413,940 | 2010-11-15 | ||
| US42146210P | 2010-12-09 | 2010-12-09 | |
| US61/421,462 | 2010-12-09 | ||
| PCT/US2011/060666 WO2012068032A1 (en) | 2010-11-15 | 2011-11-14 | Fgfr1 extracellular domain combination therapies |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137015424A Division KR20130114676A (ko) | 2010-11-15 | 2011-11-14 | Fgfr1 세포밖 도메인 조합치료 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180053420A KR20180053420A (ko) | 2018-05-21 |
| KR101910779B1 true KR101910779B1 (ko) | 2018-10-22 |
Family
ID=44993965
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187012882A Expired - Fee Related KR101910779B1 (ko) | 2010-11-15 | 2011-11-14 | Fgfr1 세포밖 도메인 조합치료 |
| KR1020137015424A Ceased KR20130114676A (ko) | 2010-11-15 | 2011-11-14 | Fgfr1 세포밖 도메인 조합치료 |
| KR1020137015394A Ceased KR20130124513A (ko) | 2010-11-15 | 2011-11-14 | 가용성 fgfr1 융합 단백질의 상승된 투약량에 의한 암 치료 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020137015424A Ceased KR20130114676A (ko) | 2010-11-15 | 2011-11-14 | Fgfr1 세포밖 도메인 조합치료 |
| KR1020137015394A Ceased KR20130124513A (ko) | 2010-11-15 | 2011-11-14 | 가용성 fgfr1 융합 단백질의 상승된 투약량에 의한 암 치료 |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP2640377B1 (cg-RX-API-DMAC7.html) |
| JP (4) | JP6178240B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR101910779B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN107050426A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2011329125B2 (cg-RX-API-DMAC7.html) |
| BR (2) | BR112013012040A2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2817537A1 (cg-RX-API-DMAC7.html) |
| EA (2) | EA025828B1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL226248A0 (cg-RX-API-DMAC7.html) |
| MX (2) | MX349293B (cg-RX-API-DMAC7.html) |
| NZ (4) | NZ610487A (cg-RX-API-DMAC7.html) |
| SG (2) | SG190248A1 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2012068032A1 (cg-RX-API-DMAC7.html) |
| ZA (2) | ZA201303501B (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160030956A (ko) * | 2013-07-05 | 2016-03-21 | 인테그라 메디컬 인코포레이티드 | 구강 조성물 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| WO2013074492A1 (en) | 2011-11-14 | 2013-05-23 | Five Prime Therapeutics, Inc. | Methods of treating cancer |
| CA2908391A1 (en) * | 2013-05-01 | 2014-11-06 | Five Prime Therapeutics, Inc. | Methods of treating cancer |
| WO2014190147A2 (en) * | 2013-05-23 | 2014-11-27 | Five Prime Therapeutics, Inc. | Methods of treating cancer |
| WO2015066452A2 (en) * | 2013-11-01 | 2015-05-07 | Foundation Medicine, Inc. | Methods of treating pediatric cancers |
| MX394623B (es) | 2016-02-04 | 2025-03-24 | Ads Therapeutics Llc | Tecnología de sinergismo anticuerpo-fármaco para el tratamiento de enfermedades. |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007014123A2 (en) | 2005-07-22 | 2007-02-01 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| WO2008065543A2 (en) | 2006-11-28 | 2008-06-05 | Centelion | Modified soluble fgf receptor fc fusions with improved biological activity |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| EP0401384B1 (en) | 1988-12-22 | 1996-03-13 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
| US5288855A (en) | 1989-01-23 | 1994-02-22 | Farmitalia Carlo Erba | Extracellular form of the human fibroblast growth factor receptor |
| WO1991000916A2 (en) | 1989-07-06 | 1991-01-24 | The Regents Of The University Of California | Receptors for fibroblast growth factors |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| ATE243253T1 (de) | 1990-07-06 | 2003-07-15 | Rhone Poulenc Rorer Internat H | Rezeptoren der wachstumsfaktoren aus fibroblasten |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US5229501A (en) | 1991-01-11 | 1993-07-20 | Chiron Corporation | Expression and use of human fibroblast growth factor receptor |
| AU1674292A (en) | 1991-03-15 | 1992-10-21 | Synergen, Inc. | Pegylation of polypeptides |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| KR100335584B1 (ko) | 1992-10-28 | 2002-11-29 | 제넨테크, 인코포레이티드 | 혈관내피세포성장인자에대한길항제 |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| CN104231078A (zh) | 1997-04-07 | 2014-12-24 | 基因技术股份有限公司 | 抗-血管内皮生长因子的抗体 |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| DE69829891T2 (de) | 1997-04-07 | 2005-10-06 | Genentech, Inc., South San Francisco | Anti-VEGF Antikörper |
| AU6366999A (en) | 1998-10-30 | 2000-05-22 | Takeda Chemical Industries Ltd. | Betacellulin protein-containing preparations |
| WO2000046380A2 (en) | 1999-02-08 | 2000-08-10 | Chiron Corporation | Fibroblast growth factor receptor-immunoglobulin fusion |
| US6703020B1 (en) | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| PT1292335E (pt) | 2000-06-23 | 2007-08-13 | Bayer Schering Pharma Ag | Combinações e composições que interferem na função de receptores vegf/vegf e angiopoietina/ tie e a sua utilização (ii) |
| US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| KR100976076B1 (ko) | 2003-05-22 | 2010-08-17 | 아보트 러보러터리즈 | 인다졸, 벤즈이속사졸 및 벤즈이소티아졸 키나제 억제제 |
| RS20150135A1 (sr) | 2003-05-30 | 2015-08-31 | Genentech Inc. | Tretman sa anti-vegf antitelima |
| WO2005044853A2 (en) | 2003-11-01 | 2005-05-19 | Genentech, Inc. | Anti-vegf antibodies |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
| WO2006076288A2 (en) | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
| WO2006081430A2 (en) | 2005-01-27 | 2006-08-03 | Five Prime Therapeutics, Inc. | Leader sequences for directing secretion of polypeptides and methods for production thereof |
| ZA200903134B (en) * | 2006-11-28 | 2010-08-25 | Centelion | Modified soluble FGF receptor FC fusions with improved biological activity |
| TWI468417B (zh) | 2007-11-30 | 2015-01-11 | Genentech Inc | 抗-vegf抗體 |
| PT2498799T (pt) * | 2009-11-13 | 2016-11-04 | Five Prime Therapeutics Inc | Utilização de proteínas do domínio extracelular rfcf1 para tratar cancros caracterizados por mutações ativadoras dependentes de ligando em rfcf2 |
-
2011
- 2011-11-14 MX MX2013005387A patent/MX349293B/es active IP Right Grant
- 2011-11-14 BR BR112013012040A patent/BR112013012040A2/pt not_active IP Right Cessation
- 2011-11-14 EA EA201390716A patent/EA025828B1/ru not_active IP Right Cessation
- 2011-11-14 JP JP2013538984A patent/JP6178240B2/ja not_active Expired - Fee Related
- 2011-11-14 BR BR112013012041A patent/BR112013012041A2/pt not_active IP Right Cessation
- 2011-11-14 KR KR1020187012882A patent/KR101910779B1/ko not_active Expired - Fee Related
- 2011-11-14 EP EP11784918.2A patent/EP2640377B1/en active Active
- 2011-11-14 NZ NZ610487A patent/NZ610487A/en not_active IP Right Cessation
- 2011-11-14 CN CN201710017991.8A patent/CN107050426A/zh active Pending
- 2011-11-14 CA CA2817537A patent/CA2817537A1/en not_active Abandoned
- 2011-11-14 WO PCT/US2011/060666 patent/WO2012068032A1/en not_active Ceased
- 2011-11-14 AU AU2011329125A patent/AU2011329125B2/en not_active Ceased
- 2011-11-14 EP EP11790705.5A patent/EP2640406A1/en not_active Withdrawn
- 2011-11-14 WO PCT/US2011/060661 patent/WO2012068030A1/en not_active Ceased
- 2011-11-14 SG SG2013036355A patent/SG190248A1/en unknown
- 2011-11-14 SG SG2013036348A patent/SG190788A1/en unknown
- 2011-11-14 EA EA201390722A patent/EA201390722A1/ru unknown
- 2011-11-14 KR KR1020137015424A patent/KR20130114676A/ko not_active Ceased
- 2011-11-14 NZ NZ703919A patent/NZ703919A/en not_active IP Right Cessation
- 2011-11-14 CN CN201180064851.7A patent/CN103347514B/zh not_active Expired - Fee Related
- 2011-11-14 AU AU2011329127A patent/AU2011329127B2/en not_active Ceased
- 2011-11-14 NZ NZ703786A patent/NZ703786A/en not_active IP Right Cessation
- 2011-11-14 MX MX2013005388A patent/MX2013005388A/es unknown
- 2011-11-14 NZ NZ610538A patent/NZ610538A/en not_active IP Right Cessation
- 2011-11-14 CA CA2817583A patent/CA2817583A1/en not_active Abandoned
- 2011-11-14 KR KR1020137015394A patent/KR20130124513A/ko not_active Ceased
- 2011-11-14 JP JP2013538985A patent/JP5945277B2/ja not_active Expired - Fee Related
-
2013
- 2013-05-09 IL IL226248A patent/IL226248A0/en unknown
- 2013-05-09 IL IL226252A patent/IL226252B/en active IP Right Grant
- 2013-05-14 ZA ZA2013/03501A patent/ZA201303501B/en unknown
- 2013-05-16 ZA ZA2013/03573A patent/ZA201303573B/en unknown
-
2016
- 2016-05-27 JP JP2016106022A patent/JP2016196475A/ja active Pending
- 2016-09-08 JP JP2016175357A patent/JP2017019843A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007014123A2 (en) | 2005-07-22 | 2007-02-01 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with fgfr fusion proteins |
| WO2008065543A2 (en) | 2006-11-28 | 2008-06-05 | Centelion | Modified soluble fgf receptor fc fusions with improved biological activity |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160030956A (ko) * | 2013-07-05 | 2016-03-21 | 인테그라 메디컬 인코포레이티드 | 구강 조성물 |
| KR102443570B1 (ko) | 2013-07-05 | 2022-09-14 | 인테그라 메디컬 인코포레이티드 | 구강 조성물 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8951972B2 (en) | FGFR1 extracellular domain combination therapies for lung cancer | |
| US8481038B2 (en) | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins | |
| EP2699590B1 (en) | Endoglin polypeptides and uses thereof | |
| JP2016196475A (ja) | Fgfr1細胞外ドメイン併用療法 | |
| EP3851118A1 (en) | Endoglin peptides to treat fibrotic diseases | |
| CN105307669A (zh) | 治疗癌症的方法 | |
| AU2015258172B2 (en) | Fgfr1 extracellular domain combination therapies | |
| AU2015249133C1 (en) | Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins | |
| HK40055818A (en) | Endoglin peptides to treat fibrotic diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| A201 | Request for examination | ||
| PA0104 | Divisional application for international application |
St.27 status event code: A-0-1-A10-A16-div-PA0104 St.27 status event code: A-0-1-A10-A18-div-PA0104 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
Fee payment year number: 1 St.27 status event code: A-2-2-U10-U12-oth-PR1002 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PR1001 | Payment of annual fee |
Fee payment year number: 4 St.27 status event code: A-4-4-U10-U11-oth-PR1001 |
|
| PC1903 | Unpaid annual fee |
Not in force date: 20221017 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE St.27 status event code: A-4-4-U10-U13-oth-PC1903 |
|
| PC1903 | Unpaid annual fee |
Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20221017 St.27 status event code: N-4-6-H10-H13-oth-PC1903 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |